Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

NCT05506969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Plague, Pneumonic
Plague
Vaccine-Preventable Diseases

Interventions

BIOLOGICAL: rF1V-1018
BIOLOGICAL: rF1V vaccine

Sponsor

Dynavax Technologies Corporation

Collaborators

[object Object]